The nine-year wait for new clinical data on Promore Pharma’s ensereptide has ended in disaster, with the failure of the polypeptide to reduce scarring in a midphase trial wounding the biotech’s share price.
[Fierce Biotech]
Home Newsletters Dermal Cell News Promore’s Scar Trial Leaves Deep Wound As Phase II Fail Sends Stock...
